Department of Radiotherapy & Oncology, Rizhao Central Hospital, Rizhao, China.
Department of Radiotherapy & Oncology, The affiliated Suzhou Hospital of Nanjing Medical University, Gusu School, Nanjing Medical University, Suzhou, China.
Ann Med. 2023;55(2):2242254. doi: 10.1080/07853890.2023.2242254.
The Naples prognosis score (NPS) is a novel prognostic biomarker-based immune and nutritional status and that can be used to evaluate prognosis. Our study aimed to investigate the prognostic role of NPS in SCLC patients.
Patients treated with chemoradiotherapy were retrospectively analyzed between June 2012 and August 2017. We divided patients into three groups depending on the NPS: group 0, = 31; group 1, = 100; and group 2, = 48, and associations between clinical characteristics and NPS group were analyzed. The univariable and multivariable Cox analyses were used to evaluate the prognostic value of clinicopathological characteristics and laboratory indicators for overall survival (OS) and progression-free survival (PFS).
Data from 179 patients were analyzed. Treatment modality ( < 0.001) and serum CEA ( = 0.03) were significantly different among the NPS groups. The age, sex, smoking status, KPS, Karnofsky performance score (KPS), disease extent, and number of metastatic sites were not correlated with NPS (all > 0.05). KPS, disease extent, prophylactic cranial irradiation, treatment response and NPS Group were associated with OS. In addition, KPS, disease extent, prophylactic cranial irradiation, treatment response and NPS Group were associated with PFS. Multivariate analysis results showed that NPS was identified as an independent prognostic factor for OS (Group 1: hazard ratio [HR] = 2.704, 95% confidence interval [CI] = 1.403-5.210; = 0.003; Group 2: HR = 5.154, 95% CI = 2.614-10.166; < 0.001) and PFS (Group 1: HR = 2.018, 95% CI = 1.014-4.014; = 0.045; Group 2: HR = 3.339, 95% CI = 1.650-6.756; = 0.001).
NPS is related to clinical outcomes in patients with SCLC.
那不勒斯预后评分（NPS）是一种新型的基于预后生物标志物的免疫和营养状况评分，可以用于评估预后。我们的研究旨在探讨 NPS 在小细胞肺癌（SCLC）患者中的预后作用。
回顾性分析了 2012 年 6 月至 2017 年 8 月期间接受放化疗的患者。我们根据 NPS 将患者分为三组：NPS=0 组，n=31；NPS=1 组，n=100；NPS=2 组，n=48，并分析了临床特征与 NPS 组之间的关系。采用单变量和多变量 Cox 分析评估临床病理特征和实验室指标对总生存期（OS）和无进展生存期（PFS）的预后价值。
共分析了 179 例患者的数据。NPS 组之间的治疗方式（<0.001）和血清 CEA（=0.03）差异有统计学意义。年龄、性别、吸烟状态、KPS、卡氏功能状态评分（KPS）、疾病程度和转移部位数量与 NPS 无相关性（均>0.05）。KPS、疾病程度、预防性颅脑照射、治疗反应和 NPS 组与 OS 相关。此外，KPS、疾病程度、预防性颅脑照射、治疗反应和 NPS 组与 PFS 相关。多变量分析结果显示，NPS 是 OS（NPS1：风险比[HR] =2.704，95%置信区间[CI] =1.403-5.210；=0.003；NPS2：HR=5.154，95%CI=2.614-10.166；<0.001）和 PFS（NPS1：HR=2.018，95%CI=1.014-4.014；=0.045；NPS2：HR=3.339，95%CI=1.650-6.756；=0.001）的独立预后因素。
NPS 与 SCLC 患者的临床结局相关。
